{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:53:06Z","timestamp":1792788786041,"version":"4.5.0"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:00Z","timestamp":1457654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dentistry Journal"],"abstract":"<jats:p>The ideal anticoagulant is oral, has a wide therapeutic range, predictable pharmacokinetics and pharmacodynamics, a rapid onset of action, an available antidote, minimal side effects and minimal interactions with other drugs or food. With the development of the novel direct oral anticoagulants (DOAC), we now have an alternative to the traditional vitamin K antagonists (VKA) for the prevention and treatment of thrombosis. DOACs have limited monitoring requirements and very predictable pharmacokinetic profiles. They were shown to be non-inferior or superior to VKA in the prophylaxis or treatment of thromboembolic events. Particularly in terms of safety they were associated with less major bleeding, including intracranial bleeding, thus providing a superior benefit for the prevention of stroke in patients with atrial fibrillation. Despite these advantages, there are remaining limitations with DOACs: their dependence on renal and hepatic function for clearance and the lack of an approved reversal agent, whereas such antidotes are successively being made available. DOACs do not need regular monitoring to assess the treatment effect but, on the other hand, they interact with other drugs and interfere with functional coagulation assays. From a practical point of view, the properties of oral administration, simple dosing without monitoring, a short half-life allowing for the possibility of uncomplicated switching or bridging, and proven safety overwhelm the disadvantages, making them an attractive option for short- or long-term anticoagulation.<\/jats:p>","DOI":"10.3390\/dj4010005","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T11:03:45Z","timestamp":1457953425000},"page":"5","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["New Direct Oral Anticoagulants (DOAC) and Their Use Today"],"prefix":"10.3390","volume":"4","author":[{"given":"Heike","family":"Schwarb","sequence":"first","affiliation":[{"name":"Heike Schwarb, Diagnostic Hematology, University Hospital Basel, CH-4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tsakiris","sequence":"additional","affiliation":[{"name":"Heike Schwarb, Diagnostic Hematology, University Hospital Basel, CH-4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,3,11]]},"reference":[{"key":"ref_1","first-page":"S13","article-title":"GARFIELD-AF\u2013First data on healthcare of patients with atrial fibrillation in Germany","volume":"140","author":"Haas","year":"2015","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.12969","article-title":"Recommendation on the nomenclature for oral anticoagulants: Communication from the SSC of the ISTH","volume":"13","author":"Barnes","year":"2015","journal-title":"J. Thromb. Haemost"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0049-3848(10)70147-X","article-title":"Factor Xa and thrombin as targets for new oral anticoagulants","volume":"127","author":"Weitz","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1074248415578172","article-title":"Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies","volume":"20","author":"Perzborn","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-014-0228-0","article-title":"Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban","volume":"54","author":"Frost","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40265-014-0261-1","article-title":"Edoxaban: An update on the new oral direct factor Xa inhibitor","volume":"74","author":"Bounameaux","year":"2014","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1161\/CIRCOUTCOMES.114.001556","article-title":"Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation","volume":"8","author":"Lip","year":"2015","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/CIRCULATIONAHA.105.505636","article-title":"Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease","volume":"113","author":"Newby","year":"2006","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/pds.1556","article-title":"Risk factors for nonadherence to warfarin: Results from the IN-RANGE study","volume":"17","author":"Platt","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/FTD.0000000000000247","article-title":"Laboratory monitoring\u2013A turning point in the use of new oral anticoagulants","volume":"38","author":"Scridon","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: Pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40268-014-0045-9","article-title":"Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C","volume":"14","author":"Chin","year":"2014","journal-title":"Drugs R D"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.seminhematol.2014.03.007","article-title":"Direct oral anticoagulants\u2014Interference with laboratory tests and mechanism of action","volume":"51","author":"Tsakiris","year":"2014","journal-title":"Semin. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"Stangier","year":"2010","journal-title":"Thromb. Haemost"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.07.021","article-title":"Safety of intravenous thrombolysis among stroke patients taking new oral anticoagulants-case series and systematic review of reported cases","volume":"24","author":"Shahjouei","year":"2015","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2011-10-378950","article-title":"How I treat with anticoagulants in 2012: New and old anticoagulants, and when and how to switch","volume":"119","author":"Schulman","year":"2012","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/EJA.0b013e32833f6f6f","article-title":"Regional anaesthesia and antithrombotic agents: Recommendations of the european society of anaesthesiology","volume":"27","author":"Gogarten","year":"2010","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.acvd.2011.09.001","article-title":"Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasi","volume":"104","author":"Sie","year":"2011","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jth.13178","article-title":"Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure","volume":"14","author":"Douketis","year":"2016","journal-title":"J. Thromb. Haemost"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/17474086.2016.1135046","article-title":"Andexanet Alfa for the Reversal of Factor Xa inhibitor related Anticoagulation","volume":"9","author":"Ghadimi","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH14-11-0982","article-title":"Reversal of anticoagulants: An overview of current developments","volume":"113","author":"Greinacher","year":"2015","journal-title":"Thromb. Haemost"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40164-015-0020-3","article-title":"Novel antidotes for target specific oral anticoagulants","volume":"4","author":"Das","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bjh.13821","article-title":"In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate","volume":"172","author":"Barco","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dibu, J.R., Weimer, J.M., Ahrens, C., Manno, E., and Frontera, J.A. (2015). The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage. Neurocrit. Care, in press.","DOI":"10.1007\/s12028-015-0213-y"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1111\/jth.12949","article-title":"Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: A re-appraisal","volume":"13","author":"Dzik","year":"2015","journal-title":"J. Thromb. Haemost"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Larsen, T.B., Nielsen, P.B., Skjoth, F., Rasmussen, L.H., and Lip, G.Y.H. (2014). Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: A semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114445"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S0049-3848(14)50021-7","article-title":"Guidelines for treatment and prevention of venous thromboembolism among patients with cancer","volume":"133","author":"Kuderer","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_39","first-page":"343","article-title":"Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism","volume":"11","author":"Chan","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1753944710387808","article-title":"New parenteral anticoagulants in development","volume":"5","author":"Lecumberri","year":"2011","journal-title":"Ther. Adv. Cardiovasc. Dis."}],"container-title":["Dentistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2304-6767\/4\/1\/5\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:20:34Z","timestamp":1760210434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2304-6767\/4\/1\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["dj4010005"],"URL":"https:\/\/doi.org\/10.3390\/dj4010005","relation":{},"ISSN":["2304-6767"],"issn-type":[{"value":"2304-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,11]]}}}